Efavirenz trough levels are not associated with virological failure throughout therapy with 800 mg daily and a rifampicin-containing antituberculosis regimen | Zendy

Luís F. LópezCortés | Zendy; Rosa Ruiz-Valderas | Zendy; Josefa RuizMorales | Zendy; Eva León | Zendy; Antonio Vergara de Campos | Zendy; Ana MarínNiebla | Zendy; Manuel Márquez | Zendy; Fernando Lozano | Zendy; Román Valiente | Zendy

Open Access

Efavirenz trough levels are not associated with virological failure throughout therapy with 800 mg daily and a rifampicin-containing antituberculosis regimen

Author(s) -

Luís F. LópezCortés,

Rosa Ruiz-Valderas,

Josefa RuizMorales,

Eva León,

Antonio Vergara de Campos,

Ana MarínNiebla,

Manuel Márquez,

Fernando Lozano,

Román Valiente

Publication year - 2006

Publication title -

journal of antimicrobial chemotherapy

Language(s) - English

Resource type - Journals

SCImago Journal Rank - 2.124

H-Index - 194

eISSN - 1460-2091

pISSN - 0305-7453

DOI - 10.1093/jac/dkl357

Subject(s) - efavirenz , regimen , rifampicin , cmin , medicine , tuberculosis , human immunodeficiency virus (hiv) , pharmacology , antiretroviral therapy , virology , pharmacokinetics , viral load , cmax , pathology

To assess the safety and efficacy of efavirenz 800 mg daily in HIV-infected patients with tuberculosis receiving a rifampicin-containing regimen and to analyse whether a relationship exists between efavirenz Cmin and its virological efficacy.

The content you want is available to Zendy users.

Already have an account? Click here to sign in.

Having issues? You can contact us here

Accelerating Research